Literature DB >> 17045571

Estradiol regulates the insulin-like growth factor-I (IGF-I) signalling pathway: a crucial role of phosphatidylinositol 3-kinase (PI 3-kinase) in estrogens requirement for growth of MCF-7 human breast carcinoma cells.

Laurence Bernard1, Christine Legay, Eric Adriaenssens, Alexandra Mougel, Jean-Marc Ricort.   

Abstract

Estrogens can stimulate the proliferation of estrogen-responsive breast cancer cells by increasing their proliferative response to insulin-like growth factors. With a view to investigating the molecular mechanisms implicated, we studied the effect of estradiol on the expression of proteins implicated in the insulin-like growth factor signalling pathway. Estradiol dose- and time-dependently increased the expression of insulin receptor substrate-1 and the p85/p110 subunits of phosphatidylinositol 3-kinase but did not change those of ERK2 and Akt/PKB. ICI 182,780 did not inhibit estradiol-induced IRS-1 and p85 expression. Moreover, two distinct estradiol-BSA conjugate compounds were as effective as estradiol in inducing IRS-1 and p85/p110 expression indicating the possible implication of an estradiol membrane receptor. Comparative analysis of steroids-depleted and steroids-treated cells showed that IGF-I only stimulates cell growth in the latter condition. Nevertheless, expression of a constitutively active form of PI 3-kinase in steroid-depleted cells triggers proliferation. These results demonstrate that estradiol positively regulates essential proteins of the IGF signalling pathway and put in evidence that phosphatidylinositol 3-kinase plays a central role in the synergistic pro-proliferative action of estradiol and IGF-I.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17045571     DOI: 10.1016/j.bbrc.2006.09.116

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  6 in total

1.  Efficacy and safety of the combination of metformin, everolimus and exemestane in overweight and obese postmenopausal patients with metastatic, hormone receptor-positive, HER2-negative breast cancer: a phase II study.

Authors:  Clinton Yam; Francisco J Esteva; Miral M Patel; Akshara S Raghavendra; Naoto T Ueno; Stacy L Moulder; Kenneth R Hess; Girish S Shroff; Silvia Hodge; Kimberly H Koenig; Mariana Chavez Mac Gregor; Robin L Griner; Sai-Ching J Yeung; Gabriel N Hortobagyi; Vicente Valero
Journal:  Invest New Drugs       Date:  2019-01-05       Impact factor: 3.850

Review 2.  Insulin receptor substrates (IRSs) and breast tumorigenesis.

Authors:  Bonita Tak-Yee Chan; Adrian V Lee
Journal:  J Mammary Gland Biol Neoplasia       Date:  2008-11-22       Impact factor: 2.673

Review 3.  Why estrogens matter for behavior and brain health.

Authors:  Liisa A M Galea; Karyn M Frick; Elizabeth Hampson; Farida Sohrabji; Elena Choleris
Journal:  Neurosci Biobehav Rev       Date:  2016-03-31       Impact factor: 8.989

Review 4.  Estrogen-IGF-1 interactions in neuroprotection: ischemic stroke as a case study.

Authors:  Farida Sohrabji
Journal:  Front Neuroendocrinol       Date:  2014-05-29       Impact factor: 8.606

Review 5.  AKT1/BRCA1 in the control of homologous recombination and genetic stability: the missing link between hereditary and sporadic breast cancers.

Authors:  Josée K Guirouilh-Barbat; Therese Wilhelm; Bernard S Lopez
Journal:  Oncotarget       Date:  2010-12

6.  Hormone replacement therapy enhances IGF-1 signaling in skeletal muscle by diminishing miR-182 and miR-223 expressions: a study on postmenopausal monozygotic twin pairs.

Authors:  Fabiola Olivieri; Maarit Ahtiainen; Raffaella Lazzarini; Eija Pöllänen; Miriam Capri; Maria Lorenzi; Gianluca Fulgenzi; Maria C Albertini; Stefano Salvioli; Markku J Alen; Urho M Kujala; Giulia Borghetti; Lucia Babini; Jaakko Kaprio; Sarianna Sipilä; Claudio Franceschi; Vuokko Kovanen; Antonio D Procopio
Journal:  Aging Cell       Date:  2014-07-18       Impact factor: 9.304

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.